3. Results
hepatitis B, AIDS, comorbidity, virological failure, renal toxicity, toxicity, infection, Dyslipidaemia, hypertension, non-AIDS
ADVERSE EVENT, AIDS, DYSLIPIDAEMIA, HYPERTENSION, CHRONIC LIVER DISEASE
The cohort evaluated 1032 patients from 13 centers in Spain. Baseline characteristics are summarized in The presence of comorbidity was diagnosed in 617 patients (59.8%), and 192 (18.6%) were with three or more comorbidities. Dyslipidaemia was the most frequent one (20.4%), followed by hypertension (11.5%) and chronic liver disease (10.3%). Patients with associated comorbidities were older than those without, In addition, 27.9% (192) of overall patients had been diagnosed with hepatitis B virus infection, but only 10/192 (5.3%) presented a positive HBs antigen during the switch to DTG+3TC. On the other hand, 3/56 patients (5.7%) in the comorbidity group showed positive HBs antigen and were on treatment with entecavir. No issues were found within this aspect.During follow-up, available data provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. Nevertheless, there is a tendency related to more virological failures in the groups without comorbidities or AIDS. In those patients with virological failure, no resistance mutations were found when drug resistance tests were performed.Immune status was assessed through the median baseline CD4+ and CD8+ lymphocyte count and CD4+/CD8+ ratio (Regarding immune status, patients with AIDS presented, as expected, a lower lymphocyte count (around 150–200 cells/mm3 less than non-AIDS patients) without paired data analysis. Nevertheless, the absolute value of CD8+ lymphocytes remained constant in both groups. This trend translates into a lower CD4+/CD8+ ratio in the AIDS group up to week 48 of dual DTG plus 3TC therapy.Adverse events (AEs) were scarce and only reported in 14 patients (1.4%). They included renal toxicity in 5 (0.5%), central nervous system toxicity in 8 (0.8%), and gastrointestinal issues in 1 (0.1%). Only three (0.29%) patients discontinued treatment because of AEs.